Board summary
Key figures
31,602
Registered population
54.7% aged 18–64
29.3%
Aged 65+
ICB 20.0% · England 17.9%
2.6%
Ethnic minority (non-White)
1.1% Asian · England 9.6%
0.0%
In IMD quintile 1
ICB 30.6% · England 21.0%
0
Core20 residents (est.)
Resident basis; registered basis 0 · see page 3
6,859
Hypertension register
+7.64% in 3 yrs · England +5.60%
319
SMI register
25.9% of Wyre's
881
COPD register
Reviews -9.76% in 3 yrs
Forecast to 2030
8,530
Hypertension patients, 2030
+1,671 on today
65.2%
QRISK ≥20% on statins, 2030
+3.03pp over 3 yrs
7.5%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Unreviewed asthma patients and falling respiratory reviews.
About 780 (785) of 2,371 asthma patients lack a 12-month review; asthma reviews changed -5.8% and COPD -9.8% over 2023 to 2025.
Lipid therapy lags England in high-risk cohorts.
Lipid therapy in QRISK ≥ 20% is 58.6% (England 63.6%), while statins in diabetes aged 40+ without CVD reached 67.0% (-2.6% change).
Breast and cervical screening exceed national benchmarks.
Cervical screening (ages 25-49) is 76.1% (England 66.8%) and breast screening is 75.6% (England 69.9%, +10.6% change over 2023 to 2024).
Population, age and ethnicity
An older population with 29.3% aged 65+ may drive local chronic care demand
Wyre Integrated Network Ltd PCN serves 31,602 registered patients. The population is distinctly older: 29.3% (9,251 patients) are aged 65+, compared to 27.1% in Wyre, 20.0% in the ICB, and 17.9% in England. Working-age adults (18–64) comprise 54.7% (Wyre 56.2%, ICB 60.4%, England 62.7%) and children (0–17) 16.1% (Wyre 16.7%, ICB 19.6%, England 19.6%). Census estimates show 97.4% White residents (Wyre 97.5%, ICB 87.8%, England 81.1%), with a 2.6% ethnic minority share. Age figures reflect registered patients, whereas ethnicity derives from Census area residents.
Age profile
65+: ICB 20.0%, England 17.9%
Ethnicity
Older people · falls rows are Wyre local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Wyre LA) | 1,506 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 82.9% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.6% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Wyre LA) | 814 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Wyre LA) | 11.5 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Average deprivation is decile 6.9 and zero registered patients live in Core20 areas
The PCN has an average IMD decile of 6.9, reflecting lower relative deprivation than Wyre (5.5 decile), England (5.5 decile) and the ICB (5.0 decile). Core20 cohort prevalence is 0.0% (estimated count 0), compared with 15.0% in Wyre, 21.0% in England and 30.6% in the ICB. Among captured practices, Core20 prevalence is 0.0% at The Village Practice and 0.0% at Lockwood GP Surgery. Average IMD decile is 6.0 at The Village Practice and 7.4 at Lockwood GP Surgery.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
319
SMI register
1.05% recorded prevalence
121
Learning disability register
0.40% recorded prevalence
18
Care homes, 526 beds
In the PCN catchment
10.6%
Provide unpaid care
Wyre, Census 2021
The PCN records 319 severe mental illness patients (1.1%) and 121 learning disability patients (0.4% vs Wyre 0.5%, ICB 0.6%, England 0.6%). The catchment includes 18 care homes with 526 beds; borough figures show 5 rough sleepers in 2025 and a 10.6% unpaid carer rate.
Severe mental illness: physical health checks
Recorded SMI prevalence is 1.1% (England 1.0%). For patients on the register, 85.2% had a blood pressure check (Beechwood Surgery 70.4%) and 83.0% had BMI recorded. From 2023 to 2025, blood pressure checks fell 0.6 pp (England +4.4 pp).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
6,859
Hypertension register
+7.64%
Register growth, 3 yrs
Wyre +7.69% · England +5.60%
−1.62pp
BP control, under 80
≤140/90 · +1.64pp aged 80+
+1,671
More patients by 2030
Forecast 8,530 (26.25%)
Hypertension case-finding and control
Hypertension recorded prevalence is 22.6% (6,859 patients), above Wyre (21.7%), NHS Lancashire and South Cumbria Integrated Care Board (17.2%) and England (15.2%), which may reflect an older demography (29.3% aged 65+) across the 31,602 registered list. For patients aged under 80 with hypertension, blood pressure control is 69.3% (England 67.8%). However, from 2023 to 2025, control fell 2.3% (or 1.6 pp), lagging England (+3.2%, +2.1 pp) and the ICB (+2.9%, +1.9 pp). Over the same period, heart failure reviews fell 6.8% to 81.5% (England +8.7%). Declines could reflect routine review capacity pressure, testable by clinic audit.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy is 58.6% (England 63.6%, ICB 61.4%, Wyre 59.8%). Statin treatment for diabetes aged 40+ without CVD is 67.0% (England 73.2%), falling 2.6% from 2023 to 2025 (England +2.1%). Lower uptake could reflect recall friction, testable by clinic audit.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 78,963 | £1.80 | £1.64 | £1.86 | £142,133 |
| Cardiovascular (all), 2025 | 124,973 | £3.71 | £3.38 | £3.33 | £463,650 |
In 2026, 78,963 items for lipid-regulating drugs cost £1.80 per item (England £1.86, ICB £1.64, Wyre £1.45). Across 78,963 items, the PCN spends £4,738 less than at England's unit cost, and £12,634 more than at NHS Lancashire and South Cumbria Integrated Care Board's unit cost.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−5.81%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−0.54%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.9% (881 patients; England 1.9%) and asthma prevalence is 8.2% (2,371 patients; England 6.6%). From 2023 to 2025, COPD reviews fell 9.8% (England +2.8%) to 74.2%, and asthma reviews fell 5.8% (England +4.4%) to 66.9%, leaving about 780 patients unreviewed. Asthma prescribing for ages 5–19 is 2,008 items per 1,000 (England 1,488). Review declines could reflect recall pressure across large registers, testable by appointment audit.
Cancer register and children's immunisation
Cancer prevalence is 6.3% (1,899 patients; England 3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months was 98.6% (3.6 pp above the 95.0% target). However, MMR dose 1 at 24 months was 87.9% (7.1 pp below target) and age-5 4-in-1 booster was 89.4% (5.6 pp below target). Queensway Medical Centre shows a 4.2 pp drop between age-5 MMR doses. Uptake gaps could reflect recall friction, testable by call-log audit.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of cancers with a known stage in NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 cases), trailing England (55.3%) and sitting 22.6 pp below the 75.0% national ambition. Staging coverage was 74.6% (8,863 of 11,883 registered cancers), and the early-stage share fell 1.2 pp from 2013 to 2022, requiring about 2,010 additional early diagnoses annually across the ICB. Wyre Integrated Network Ltd PCN records 1,899 cancer patients (6.3% prevalence vs England 3.8%), alongside 75.6% breast screening and 76.1% cervical screening (ages 25–49). Staging metrics reflect system performance rather than PCN delivery; sustaining robust recall and prompt investigation remains essential.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In Jul 2026 (provisional), Blackpool Teaching Hospitals NHS Foundation Trust achieved 67.5% on the cancer 62-day referral to treatment standard (17.5 pp below the 85.0% standard), trailing University Hospitals of Morecambe Bay NHS Foundation Trust (72.4%), NHS Lancashire and South Cumbria Integrated Care Board (73.6%), Lancashire Teaching Hospitals NHS Foundation Trust (75.0%) and England (71.2%). The 28-day faster diagnosis standard reached 71.4% (standard 75.0%), but 31-day treatment reached 98.0% against the 96.0% standard. Diagnostic 6-week waits reached 21.8% for MRI and 27.6% for non-obstetric ultrasound. These figures reflect provider performance rather than PCN pathways.
| Pathways within standard (%) | Blackpool | Lancashire | of Morecambe Bay | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 71.38 | 82.90 | 78.39 | 78.39 | 79.32 |
| 31-day treatment (96%) | 97.96 | 89.43 | 95.22 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 67.48 | 75.04 | 72.35 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Blackpool | Lancashire | of Morecambe Bay | England |
|---|---|---|---|---|
| MRI | 21.80 | 2.41 | 4.04 | 21.40 |
| CT | 16.49 | 14.97 | 13.76 | 9.92 |
| Echocardiography | 7.57 | 13.85 | 10.55 | 28.48 |
| Colonoscopy | 13.08 | 0.00 | 0.60 | 30.83 |
| Gastroscopy | 12.47 | 0.00 | 1.45 | 29.02 |
| All 15 DM01 tests | 26.54 | 26.65 | 10.44 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In Jun 2026 (provisional), Wyre residents accounted for 126,445 community service contacts across the borough, of which 72,000 involved adults aged 65 and over (56.9%). These figures describe resident activity across the borough rather than Wyre Integrated Network Ltd PCN caseloads.
Practice variation and patient experience
Phone access spans 23.5 pp and overall experience spans 18.2 pp across practices
In 2025/26, overall QOF achievement was 100.0% at Beechwood Surgery and 99.8% at Queensway Medical Centre, against England's 92.5%. For vaccination and immunisation achievement, Lockwood GP Surgery achieved 93.7%, while Beechwood Surgery achieved 100.0%, a range of 6.3 pp. At Queensway Medical Centre, vaccination personalised care adjustments reached 13.4% (England 4.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Village | 95 | 0.0 | 81.9% | 69.8% | 91.5% |
| Beechwood Surgery | 115 | 0.0 | 88.3% | 83.5% | 86.9% |
| Lockwood GP | 111 | 0.0 | 76.7% | 70.9% | 84.3% |
| Queensway | 102 | 0.0 | 64.8% | 71.8% | 73.3% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
The PCN trails England's three-year change on 18 of 25 compared measures
The PCN trails England on 18 of 25 compared three-year change measures. From 2023 to 2025, annual reviews fell 6.8% for heart failure (England +8.7%), 9.8% for COPD (England +2.8%) and 5.8% for asthma (England +4.4%), while psychosis alcohol recording fell 1.9 pp (England +5.4 pp) to 78.8% (England 81.8%). Conversely, breast screening rose +10.6% (England +8.4%) to 75.6% (England 69.9%) and cervical screening rose +1.2% (England -1.0%) to 76.1% (England 66.8%). Trailing reviews could reflect recall pressure, testable by clinic audit.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
COPD reviews
Asthma reviews
Dementia register
Alcohol record (psychosis)
Breast screening (53-70)
Cervical screening
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Wyre | Asset | PCN | Wyre |
|---|---|---|---|---|---|
| Care homes (catchment) | 18 (526 beds) | n/a | Schools (catchment) | 40 | n/a |
| Children's centres | 3 | 7 | Places of worship | 29 | 83 |
| Libraries | 2 | 6 | Food banks (VCS) | n/a | 1 |
| Day centres (VCS) | n/a | 3 | Carers support groups (VCS) | n/a | 2 |
| Primary schools (LA maintained) | 13 | 31 | Primary academies | 3 | 6 |
| Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured respiratory annual review recall
Asthma reviews fell 5.8% from 2023 to 2025 (England +4.4%) to 66.9% of 2,371 patients (about 780 unreviewed); COPD reviews fell 9.8% (England +2.8%) to 74.2% of 881. For discussion, the PCN could run a single-template respiratory recall and review inhaler prescribing, starting at the largest-volume practices. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Pharmacist-led lipid and hypertension recall
QRISK ≥ 20% lipid therapy is 58.6% (England 63.6%, ICB 61.4%). Diabetes 40+ statins (no CVD) fell 2.6% to 67.0% (England 73.2%); under-80 BP control fell 2.3% to 69.3%. For discussion, the PCN could deploy pharmacist-led recall and medicines review for untreated high-QRISK and above-target hypertension patients. Moderate effort to run.
Evidence base: delivery measure for eight care processes and three treatment targets; shortfall here is what shows up later as emergency admission.
Policy anchor: NHS Diabetes Prevention Programme and the eight care processes / three treatment targets.
Option 3
Practice phone access and recall audit
Phone access spans 23.5 pp (Queensway Medical Centre 64.8% to Beechwood Surgery 88.3%). MMR1 at 24 months is 87.9% (7.1 pp below 95.0%); SMI BP checks fell 0.6 pp (Beechwood Surgery 70.4%). Low cost, quick to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Anticipatory care planning (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| SMI physical check recall (p4) | Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure recall (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Childhood immunisation recall review (p6) | MMR dose 1 coverage at 24 months | 10YHP sickness to prevention · 95% target | PCN |
| Screening recall and safety netting (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured respiratory annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Pharmacist-led lipid and hypertension recall (p12) | Patients with QRISK ≥ 20% treated with lipid lowering therapy · Patients with diabetes (40+ yrs no history of CVD) treated with a statin (denominator incl. PCAs) · Hypertension register | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 3 · Practice phone access and recall audit (p12) | GPPS easy to contact the practice by phone · MMR dose 1 coverage at 24 months · Severe mental illness register | MHIS · From Harm to Hope | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
